Dr. Michael Jason Goldstein, MD

Dr. Goldstein practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Dr. Goldstein's NPI, 1962426601, was assigned on July 26, 2006. Dr. Goldstein graduated from Lewis Katz School of Medicine at Temple University in 1997. Dr. Goldstein holds New Jersey license 25MA09997500.

Dr. Goldstein's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Dr. Goldstein's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. The medical group on file is Hackensack Meridian Medical Group. Dmand AI also links Dr. Goldstein to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldstein practices, 2 sites in all. Vendor and product names are available with a free account.

Transplant surgery is Dr. Goldstein's primary specialty in the NPI Registry, under taxonomy code 204F00000X. Dmand AI has Dr. Goldstein's licenses on file in 2 states: New Jersey and New York.

CMS data shows 285 Medicare services from Dr. Goldstein across 8 procedure codes in 2024, for 99 Medicare patients. Medicare paid $132,216 for them.

CMS counts 99 Medicare patients who saw Dr. Goldstein in 2024. The largest group is under 65, with 45 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 28% are also on Medicaid. Their average risk score is 8.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldstein's median patient age at 64, with 30% women.

In 2024, Dr. Goldstein wrote 1,495 Medicare Part D claims for 164 patients. 77% of them were for generic drugs. CMS names the drug for 1,282 of them, across 31 drugs with 11 or more claims each, at $214,964 in total drug cost. In 2023, CMS named 1,679 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Goldstein for performance year 2024, reported as part of a group. Dr. Goldstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 168 general payments to Dr. Goldstein from 11 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 37% of the total. Veloxis Pharmaceuticals, Inc. paid the most, $69,822.

Dr. Goldstein graduated from Lewis Katz School of Medicine at Temple University in 1997.